[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

G. Leonard Baker, Jr. net worth and biography

G. Baker, Jr. Biography and Net Worth

Director of Corcept Therapeutics

G. Leonard Baker, Jr. has served as a member of our Board since 1999. Mr. Baker was a Managing Director of the General Partner of Sutter Hill Ventures, a venture capital firm in Palo Alto, California from 1973 through 2020. Mr. Baker currently serves on the boards of directors of private companies and non-profits. He received his B.A. from Yale University and his M.B.A. from Stanford University

What is G. Leonard Baker, Jr.'s net worth?: The estimated net worth of G. Leonard Baker, Jr. is at least $55.63 million as of November 21st, 2018. Baker, Jr. owns 966,838 shares of Corcept Therapeutics stock worth more than $55,631,859 as of November 23rd. This net worth estimate does not reflect any other assets that Baker, Jr. may own. Learn More about G. Leonard Baker, Jr.'s net worth.
How do I contact G. Leonard Baker, Jr.?: The corporate mailing address for Baker, Jr. and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on G. Leonard Baker, Jr.'s contact information.
Has G. Leonard Baker, Jr. been buying or selling shares of Corcept Therapeutics?: G. Leonard Baker, Jr. has not been actively trading shares of Corcept Therapeutics during the past quarter. Learn More on G. Leonard Baker, Jr.'s trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, insiders at the biotechnology company sold shares 32 times. They sold a total of 269,472 shares worth more than $7,991,445.07. The most recent insider tranaction occured on November, 11th when Director Daniel N. Swisher, Jr. sold 2,200 shares worth more than $131,736.00. Insiders at Corcept Therapeutics own 20.5% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 11/11/2024.

G. Leonard Baker, Jr. Insider Trading History at Corcept Therapeutics

G. Leonard Baker, Jr. Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $57.54

$56.14

$57.71

50 Day Range

MA: $48.41

$38.47

$59.60

2 Week Range

Now: $57.54

$20.84

$61.66

Volume

676,106 shs

Average Volume

1,129,428 shs

Market Capitalization

$6.03 billion

P/E Ratio

45.67

Dividend Yield

N/A

Beta

0.45